(Q36223724)

12 August 2017

1 reference

title

Updated clinical pharmacologic considerations for HIV-1 protease inhibitors (English)

1 reference

12 August 2017

Peter L Anderson

1

1 reference

12 August 2017

Courtney V Fletcher

series ordinal

2

1 reference

12 August 2017

publication date

1 April 2004

1 reference

12 August 2017

published in

Current HIV/AIDS reports

1 reference

12 August 2017

volume

1

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

33-39

1 reference

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-004-0005-Z

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-004-0005-Z

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

12 December 2020

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

1 reference

12 December 2020

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

12 December 2020

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

12 December 2020

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

1 reference

12 December 2020

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture

1 reference

12 December 2020

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

12 December 2020

Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens

1 reference

12 December 2020

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

The triple combination indinavir-zidovudine-lamivudine is highly synergistic

1 reference

12 December 2020

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

1 reference

12 December 2020

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

1 reference

12 December 2020

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

1 reference

12 December 2020

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

1 reference

12 December 2020

Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

1 reference

12 December 2020

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 reference

12 December 2020

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

12 December 2020

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

12 December 2020

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy

1 reference

12 December 2020

Natural history of HIV infection in the era of combination antiretroviral therapy

1 reference

12 December 2020

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

Pharmacologic considerations for therapeutic success with antiretroviral agents

1 reference

12 December 2020

Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter

1 reference

12 December 2020

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

12 December 2020

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

1 reference

12 December 2020

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

12 December 2020

10.1007/S11904-004-0005-Z

Identifiers

DOI

1 reference

release_wyqaqba4rjefxhx74c4ichi6wm

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wyqaqba4rjefxhx74c4ichi6wm

24 November 2022

mapped directly with Wikidata item

1 reference